AxoGen Statistics
Total Valuation
AxoGen has a market cap or net worth of $276.52 million. The enterprise value is $313.72 million.
| Market Cap | 276.52M |
| Enterprise Value | 313.72M |
Important Dates
The next confirmed earnings date is Thursday, May 2, 2024, before market open.
| Earnings Date | May 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AxoGen has 43.21 million shares outstanding. The number of shares has increased by 1.89% in one year.
| Shares Outstanding | 43.21M |
| Shares Change (YoY) | +1.89% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 5.05% |
| Owned by Institutions (%) | 77.24% |
| Float | 33.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.75 |
| Forward PS | 1.52 |
| PB Ratio | 2.91 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.76.
| Current Ratio | 2.89 |
| Quick Ratio | 2.04 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.66 |
Financial Efficiency
Return on equity (ROE) is -22.40% and return on invested capital (ROIC) is -12.78%.
| Return on Equity (ROE) | -22.40% |
| Return on Assets (ROA) | -11.20% |
| Return on Capital (ROIC) | -12.78% |
| Revenue Per Employee | $373,268 |
| Profits Per Employee | -$50,977 |
| Employee Count | 426 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 1.49 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.50% in the last 52 weeks. The beta is 1.02, so AxoGen's price volatility has been similar to the market average.
| Beta (1Y) | 1.02 |
| 52-Week Price Change | -33.50% |
| 50-Day Moving Average | 8.70 |
| 200-Day Moving Average | 7.14 |
| Relative Strength Index (RSI) | 25.70 |
| Average Volume (30 Days) | 398,432 |
Short Selling Information
The latest short interest is 1.73 million, so 4.00% of the outstanding shares have been sold short.
| Short Interest | 1.73M |
| Short Previous Month | 1.70M |
| Short % of Shares Out | 4.00% |
| Short % of Float | 5.16% |
| Short Ratio (days to cover) | 4.81 |
Income Statement
In the last 12 months, AxoGen had revenue of $159.01 million and -$21.72 million in losses. Loss per share was -$0.51.
| Revenue | 159.01M |
| Gross Profit | 127.87M |
| Operating Income | -21.46M |
| Pretax Income | -21.72M |
| Net Income | -21.72M |
| EBITDA | -13.33M |
| EBIT | -18.88M |
| Loss Per Share | -$0.51 |
Balance Sheet
The company has $37.03 million in cash and $72.28 million in debt, giving a net cash position of -$35.25 million or -$0.82 per share.
| Cash & Cash Equivalents | 37.03M |
| Total Debt | 72.28M |
| Net Cash | -35.25M |
| Net Cash Per Share | -$0.82 |
| Equity / Book Value | 95.67M |
| Book Value Per Share | 2.21 |
| Working Capital | 57.57M |
Cash Flow
In the last 12 months, operating cash flow was -$5.72 million and capital expenditures -$13.87 million, giving a free cash flow of -$19.59 million.
| Operating Cash Flow | -5.72M |
| Capital Expenditures | -13.87M |
| Free Cash Flow | -19.59M |
| FCF Per Share | -$0.46 |
Margins
Gross margin is 80.42%, with operating and profit margins of -13.50% and -13.66%.
| Gross Margin | 80.42% |
| Operating Margin | -13.50% |
| Pretax Margin | -13.66% |
| Profit Margin | -13.66% |
| EBITDA Margin | -8.38% |
| EBIT Margin | -11.87% |
| FCF Margin | -12.32% |
Dividends & Yields
AxoGen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | -1.89% |
| Shareholder Yield | -1.89% |
| Earnings Yield | -7.80% |
| FCF Yield | -7.03% |
Analyst Forecast
The average price target for AxoGen is $13.60, which is 112.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.60 |
| Price Target Difference | 112.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 14.28% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 11, 1994. It was a forward split with a ratio of 105:100.
| Last Split Date | Jul 11, 1994 |
| Split Type | Forward |
| Split Ratio | 105:100 |
Scores
AxoGen has an Altman Z-Score of 0.49 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.49 |
| Piotroski F-Score | 2 |